This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessing new biomarkers for the diagnosis of GHD
Timeframe: 3 years
Measuring miRNA changes after 3 months on GH therapy
Timeframe: 3 years
Multiple linear regression models
Timeframe: 3 years
Measuring miRNA changes between daily and long-acting GH therapy
Timeframe: 3 years